Emerging Role of Circular RNAs in Cancer

Jing Liu1,2,3, Xin Zhang1,2,3, Meinan Yan1,2,3 and Hui Li1,2,3*  

1Department of Gastrointestinal Cancer Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, 2Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China, 3National Clinical Research Center for Cancer, Tianjin, China

Circular RNAs (circRNAs), which are generated mainly from back-splicing of exons in precursor mRNAs (pre-mRNAs), are a novel class of endogenous covalently closed RNA molecules. Their functions as microRNA sponges, protein scaffolds, and modulators of transcription and splicing, as well as occasional templates for polypeptide production, are beginning to be recognized, though the investigation of circRNAs is in its infancy. circRNAs play critical roles in diverse cellular processes. Aberrant expression of circRNAs in malignancies sustains cellular growth and proliferation, promotes cellular invasiveness, and circumvents cellular senescence and death, suggesting their potential for exploitation as clinical biomarkers and therapeutic targets. In this review, we highlight recent progress in research on circRNAs in cancer, emphasizing the molecular mechanisms and potential clinical value of circRNAs.

Keywords: circular RNAs, molecular mechanism, cancer, clinical application, biomarker

INTRODUCTION

Circular RNAs (circRNAs), a novel class of endogenous covalently closed RNA molecules, have attracted great attention in the past few years. They are generally derived from back-splicing of precursor mRNA (pre-mRNA), during which the 3′ splice donor sequence is joined to the downstream 5′ splice acceptor sequence (1, 2). In 1976, Sanger et al. (3) first identified the single-stranded viroid RNA in circular formats with high thermal stability via electron microscopy. Subsequently, this kind of circRNA transcript was found in hepatitis delta virus (4), yeast (5), archaea (6), fruit flies (7), and mammals (8). In 1991, Nigro et al. (9) discovered the presence of circRNA transcripts derived from the Deleted in Colon Cancer (DCC) gene in humans for the first time; subsequently, other genes, including ETS-1 gene (10), the human cytochrome P450 gene (11), the human dystrophin gene (12), and the antisense noncoding RNA in the INK4 locus (13), were identified to produce circular transcripts. However, these circRNAs were long considered as aberrant splicing by-products with low abundance and limited biological function (14).

With the development of high-throughput RNA sequencing (RNA-seq) and bioinformatics tools, numerous circRNAs have been identified. Salzman et al. (15) explored the circRNA map in pediatric acute lymphoblastic leukemia samples and revealed that large portions of spliced gene transcripts are circRNAs. Jeck et al. (16) identified >25,000 circRNAs that are not degraded by exonucleases in human fibroblasts. Circular splicing of RNA is accepted to be a general feature of gene expression, but whether these circRNAs are functional is a primary concern of researchers.

Studies to date have reported that circRNAs are dysregulated in the pathophysiologic processes of several diseases, including cardiovascular disease (17), neurodegenerative disease such as Alzheimer’s disease (18), metabolic disorder (19), diseases caused by viral infection (20), and cancer,
which is the focus of the following sections (21). Abnormal expressed circRNAs can modulate gene transcription via indirect interactions with other transcription factors, such as microRNAs (miRNAs) and RNA binding proteins (RBPs) (22, 23). Sporadic studies have also pointed out that some circRNAs containing translation initiation elements can be translated into functional proteins and peptides (24, 25). Moreover, the competitive splicing mechanism of circRNAs also affects the expression of their parent genes, thus producing biological effects (26). In addition to functioning as regulators of gene expression, circRNAs are also novel promising biomarkers for disease diagnosis and prognosis assessment due to their stable closed circular structure and tissue- and developmental stage-specific expression patterns (27, 28).

However, the understanding of circRNAs is in its infancy, and knowledge of the biological characteristics of these molecules requires further supplementation. More work is needed to explore the emerging roles of circRNAs in cancer. In this review, we introduce the biogenetic model, expression profile, and functional mechanism of circRNAs and summarize recent progress in circRNA research and their application in cancer.

**MECHANISMS FOR circRNA GENERATION**

circRNAs are divided into three main types according to their sources, namely, exonic circular RNAs (ecircRNAs), circular intronic RNAs (ciRNAs), and exon–intron circular RNAs (elicRNAs), among which ecircRNAs are the most common (29). Several circularization mechanisms produce circRNAs. These elements shorten the spatial distance between the two ends of the loop sequence and provide possibilities for back-splicing.

Intron pairing-driven circularization is mediated by 30–40 nucleotide (nt) reverse complementary sequences in the flanking regions of circularized exons; these sequences form double-stranded RNA structures and therefore promote circRNA production as cis-acting elements (2, 16). Alu is the most common reverse complementary element in mammals. In addition, some specific RBPs can bind to both sides of flanking intron sequences and bring splice donors and splice acceptors sufficiently close through protein–protein interactions (30), such as Qquaking (QKI) (31), NF90/NF110 (32), and FUS (33). In contrast, other RBPs may inhibit circRNA production. For example, adenosine deaminase acting on RNA 1 (ADAR1), a common Alu editing element, was identified to deaminate adenosine nucleosides to inosine (A-to-I editing) in regions that are complementary and proximal to the splice sites of circularized exons and destabilize intron pairing interactions, thereby antagonizing circRNA biogenesis (34). Lariat-driven circularization occurs in the process of exon skipping. This process produces a lariat intermediate containing introns and exons, which then undergo back-splicing to form circRNAs. The production of cIRNAS is a special situation in the lariat-driven model (35). CircRNA biogenesis in vivo is indeed very complicated. The expression level of a circRNA may be influenced by various circularization mechanisms. In addition, alternative splicing is a key component of circRNA production and gene expression regulation (36, 37).

**circRNA EXPRESSION AND CHARACTERISTICS**

circRNAs have been identified to be expressed widely in most organisms. The size of circRNAs ranges from <100 to several thousand nucleotides (30), and the common size reported in human cells is a few hundred nucleotides comprising 2–3 exons. The expression of most circRNAs is generally lower than that of their linear transcripts (38), but a few circular transcripts exhibit an expression level slightly or much higher than those of the their linear transcripts, such as the products of the CDR1 and Sry genes (8, 15, 16, 22). In addition, due to their unique closed circular structure, circRNAs are protected from degradation by exonucleases and are more stable than linear RNAs (16). Multiple studies have reported that circRNAs have longer half-lives than linear transcripts both in vitro and in vivo (39, 40). Moreover, circRNA expression is generally tissue- and developmental stage-specific. Several studies have shown that many circRNAs are upregulated in the nervous system (41–44), a characteristic that may be related to their posttranscriptional accumulation in neurons (45–47). Therefore, scientists hypothesized that the intracellular level of circRNAs was negatively correlated with the cell proliferation index (48). This hypothesis may explain why circRNA expression in tumor cells is generally lower than that in normal cells. Moreover, circRNAs may have higher sequence conservation than other types of RNA in mammals (41). Taken together, the high conservation, stability, and specificity of circRNAs imply that circRNAs may have multiple biological functions and clinical applications and are unlikely to be simply splicing by-products.

**TECHNIQUES FOR STUDYING circRNAs**

Although circRNAs were discovered decades ago, they could not be detected by early routine poly(A)-enriched RNA sequencing technology. Panda et al. (49) proposed a novel method, RNAse R treatment followed by polyadenylation and poly (A)+ RNA depletion (RPAD), to enrich highly pure circRNAs. In this method, total RNAs are first treated with RNase R to deplete linear RNAs. The remaining RNAs with 3'-OH ends are polyadenylated and removed by poly (A)+ RNA depletion via oligo (dT) beads. The RPAD method eliminated the interference of linear RNAs and significantly improved the reliability of the data. However, RPAD is unsuitable for joint analysis of circRNAs with other molecules such as miRNAs and mRNAs. Researchers should adopt different methods to optimize RNA sequencing libraries for the specific experimental purpose.

To date, a variety of algorithms have been developed to identify circRNAs. CircRNAs are generated primarily from pre-mRNA back-splicing, not canonical splicing; thus, the mapping algorithms used in early transcriptome analysis cannot directly match the fragments to the genome. Therefore, sequencing reads that span back-splicing sites require further genomic alignment and correction (50, 51). Various bioinformatics algorithms have been developed for circRNA annotation and quantification (51, 52). The use of two or more tools simultaneously is
TABLE 1 | Databases about circRNAs.

| Database   | Website                               | Function                                                                 | References |
|------------|---------------------------------------|--------------------------------------------------------------------------|------------|
| Circbase   | http://www.circbase.org/              | Circbase collects and integrates published circRNA data and identifies   | (53)       |
| CIRCpedia v2 | http://www.picb.ac.cn/momics/circpedia | CIRCpedia contains transcriptome data from approximately 180 samples      | (36)       |
| DeepBase v2.0 | http://rna.sysu.edu.cn/depBase/        | DeepBase v2.0 collects a total of 107,913 circRNAs, of which 92.5% were  | (54)       |
| CircRNADb  | http://202.195.183.4:8000/            | CircRNADb provides not only basic information about the chromosomal       | (55)       |
| TSCD       | http://gb.whu.edu.cn/TSCD              | TSCD collects tissue-specific circular RNAs in humans and mice           | (56)       |
| CircInteractome | http://circinteractome.nia.nih.gov/    | CircInteractome provides information about microRNA and RBP binding      | (57)       |
| CSCD       | http://gb.whu.edu.cn/CSCD              | CSCD collects circRNA data from 87 cancer cell lines and 141 normal cells,| (58)       |
| Circ2Traits | http://gyanxet-beta.com/circdb/        | Circ2Traits integrates 1,954 circular RNAs related to human diseases. The | (59)       |
| MiOncoCirc | https://nguyenjoshvo.github.io/        | MiOncoCirc collects the data of circRNA expression in different cancer    | (60)       |
| ExoRBase   | http://www.exorbase.org/              | ExoRBase collects 58330 circRNAs from 92 serum exosomal RNA sequencing   | (61)       |

*cirRNA, circular RNA; RBP, RNA binding protein.*

FUNCTIONS OF circRNAs

Numerous reports have confirmed that circRNAs can regulate gene expression directly or, more commonly, through binding with miRNAs, RBPs, and other gene expression regulators, thereby regulating various biological processes.

miRNA Sponging

miRNAs are a large class of small (~22 nt) noncoding single-stranded RNAs that can bind to their target miRNAs to inhibit their translation or promote their degradation. Recent studies have reported that many circRNAs can act as competitive endogenous RNAs (ceRNAs), binding with miRNAs through miRNA response elements (MREs) to downregulate the function of the target miRNA. The most representative example is CDR1as (antisense to the cerebellar degeneration-related protein 1 transcript), also known as ciRS-7 (22, 62). CDR1as contains 73 binding sites for miR-7, and the interaction of these two RNAs can inhibit the function of miR-7. In addition, their interaction provides a novel mechanism for miR-7 transport. Similarly, ciRSry, derived from the mouse sex-determining gene Sry, contains 16 binding sites for miR-138 and can act as a miRNA sponge (29). Notably, most circRNAs are localized mainly in the cytoplasm, indicating their availability to bind with miRNAs and regulate their function (39). However, most circRNAs do not contain multiple miRNA binding sites (29). Although this mechanism is the most widely studied mechanism of circRNAs, its importance remains to be confirmed. The abundance of most circRNAs is generally low, which also limits the universality of the miRNA sponge hypothesis.

Protein Scaffolding

CircRNAs contain many RBP binding sites in addition to MREs. For example, human antigen R (HuR) has been reported to bind with numerous circRNAs in human cervical carcinoma HeLa cells (63). CircPABPN1, derived from the PABPN1 gene, can compete with PABPN1 mRNA for binding to HuR, thereby inhibiting the translation of PABPN1. In addition, elciRNAs and ciRNAs, predominantly localized in the nucleus, were shown to be able to interact with small nuclear ribonucleoprotein U1 (snRNP U1) and enhance RNA polymerase II (Pol II) transcriptional activity on their parental gene as cis regulators (35, 64). Additionally, the binding of circRNAs to some functional proteins may affect multiple signaling pathways leading to homeostasis changes. Du et al. (65) found that the circRNA circ-Foxo3 interacted with the anti-senescence protein ID-1, the transcription factor E2F1, and the anti-stress proteins FAK and HIF1α and retained them in the cytoplasm to hinder their corresponding functions.

Translational Templates

Although circRNAs have historically been considered noncoding RNAs, several recent studies have indicated that some circRNAs contain translation initiation sites and have translational
potential (39). For example, some circRNAs with internal ribosome entry sites (IRESs) can be translated into proteins in vitro and in vivo (24). FBXW7-185aa is a novel protein encoded by circ-FBXW7 and contains an IRES (66). N6-methyladenosine (m6A), the most common RNA base modification, is abundant in circRNA sequences and can facilitate translation initiation by recruiting eIF4G2 and YTHDF3 (67). Another study in 2017 found that circ-ZNF609 contained an open reading frame and could be translated in human skeletal muscle. To date, only a few circRNAs have been reported to be involved in the translation process. Although some bioinformatics tools have been developed to predict the translation potential of circRNAs, their accuracy needs to be further improved and experimentally verified. In addition, whether these proteins or peptides formed from circRNAs have important functions needs exploration.

**Other Functions**

Moreover, the biosynthesis of circRNAs can compete with the splicing of their linear transcripts, thus affecting their expression and corresponding functions (68). Because of their stability, circRNAs can also accumulate over time and may thus act as memory molecules for the transcriptional history of a cell (69). The presence of circRNAs in vesicles also suggests their function as signaling molecules (70).

**THE FUNCTIONS OF circRNA AND CANCER**

CircRNAs are abnormally expressed in many cancers, such as lung cancer, breast cancer, digestive system cancers, ovarian cancer, and glioblastoma. Hang et al. (71) identified 185 differentially expressed circRNAs between non-small-cell lung cancer (NSCLC) tissues and adjacent normal tissues through RNA sequencing. In addition, Zeng et al. (72) detected 192 upregulated and 239 downregulated circRNAs in colorectal cancer (CRC) tissues from patients with or without pulmonary metastasis. Whether this differential expression is related to cancer development has been a focus of circRNA research.

**Cell Proliferation**

Via high-throughput sequencing, Xie et al. (73) screened a circRNA related to bladder cancer (BC), BCRC-3. BCRC-3 is poorly expressed in BC tissues and cell lines, and it can bind to miR-182-5p to act as a ceRNA, thereby upregulating the expression of p27 and inhibiting BC cell proliferation. Liang et al. (74) found that circβ-catennin was upregulated in liver cancer tissues compared to adjacent tissues. Silencing circβ-catennin significantly inhibited malignant phenotypes. Mechanistically, circβ-catennin can be translated into a 370-amino acid (aa) β-catennin isoform. This β-catennin–370aa construct competed with GSK3β to inhibit its degradation of β-catennin, thereby activating the Wnt/β-catennin pathway in liver cancer to promote tumor growth. Moreover, circACC1 has been reported to bind the regulatory β and γ subunits of AMP-activated protein kinase (AMPK), resulting in a ternary complex, which in turn activates AMPK enzyme activity and then promotes fatty acid β-oxidation and glycolysis (75). Overexpression of circACC1 can promote tumorogenesis. A positive correlation between AMPK activation and elevated circACC1 expression was identified in CRC tissues. Zhang et al. (76) revealed that circNRP1P can sponge miR-149-5p and thus affect the AKT1/mammalian target of rapamycin (mTOR) axis, acting as a tumor promoter in gastric cancer (GC). This study also suggested that circNRP1 can assemble into exosomes and participate in exosomal communication among GC cells (76).

**Invasion and Metastasis**

Recently, Hu et al. (77) identified a circRNA, circASAP1, that is associated with pulmonary metastasis after curative resection in hepatocellular carcinoma (HCC) patients. Studies have shown that circASAP1 acts as a sponge of miR-326 and miR-532-5p, which have mitogen-activated protein kinase (MAPK)1 and colony stimulating factor (CSF-1) in common as target genes, thereby promoting HCC cell invasion and macrophage infiltration. In addition, Chen et al. (78) discovered a circRNA, FECR1, derived from Friend leukemia virus integration 1 (FLI1). Overexpression of FECR1 can increase the invasiveness of breast cancer cells. Mechanism studies have shown that FECR1 can recruit TET1 and act in trans to downregulate DNM1T1, causing DNA demethylation of FLI1 and promoting cell metastasis. FECR1 may be a potential therapeutic target for metastatic breast cancer. m6A-modified circNSUN2 can form a ternary complex with insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) and high-mobility group A2 (HMG2A) to enhance HMG2A mRNA stability and subsequently promote liver metastasis in CRC (79). CircFoxo3 expression is low in high-grade prostate cancer, and overexpression of circFoxo3 in DU145 cells can inhibit the epithelial–mesenchymal transition (EMT) and reduce cell viability by enhancing Foxo3 expression (26). CircMTO1 (hsa_circRNA_104135) is significantly downregulated in HCC and can affect p21 expression by targeting miR-9 and, in turn, promote cell proliferation and invasion (80).

**Cell Cycle**

Circ-Foxo3 has been shown to bind with CDK2 and p21, leading to formation of the circ-Foxo3–p21–CDK2 ternary complex (81). CDK2 generally interacts with cyclin A/E to promote cell cycle progression, while p21 inhibits these effects. Formation of this ternary complex enhanced the inhibitory effect of p21 on CDK2, which prevented cell cycle transition from G1 to S phase and thus inhibited cell proliferation. Cheng et al. (82) found significant upregulation of circTP63 in lung squamous cell carcinoma (LUSC) tissues. CircTP63 competitively binds to miR-873-3p, thereby abolishing the inhibitory effect of miR-873-3p on its target gene Forkhead Box M1 (FOXM1). Elevated FOXM1 expression further enhances the expression of centromere protein (CENPA) and CENPB, ultimately promoting cell cycle progression and cell proliferation.

**Cell Death**

Circ-Foxo3 was reported to be downregulated in tumor tissues and cells (83). On the one hand, transfection of circ-Foxo3...
can induce apoptosis as a stress stimulus. On the other hand, highly expressed circ-Foxo3 interacts with p53 and murine double minute 2 (MDM2) and inhibits ubiquitination-mediated degradation of Foxo3 by MDM2. Overexpression of Foxo3 promotes apoptosis via its target Puma. Du et al. (84) detected abnormally increased circ-Dnmt1 expression in breast cancer tissues and cells and found that circ-Dnmt1 interacted with p53 and AUF1, leading to their nuclear translocation, thus mediating cell autophagy. Transfection of circ-Dnmt1 into breast cancer cells can induce autophagy to maintain cell homeostasis and ultimately promote cell proliferation and tumorigenesis. Furthermore, Chen et al. (85) found that circHIPK3 expression was upregulated in STK11 mutant lung cancer cell lines. Silencing circHIPK3 can induce autophagy through the miR124-3p–STAT3–PRKAA/AMPKa axis. Thus, circHIPK3 is a key upstream regulator of autophagy in lung cancer.

Others
CircRNAs can also regulate the drug sensitivity of tumors. By high-throughput sequencing of circRNAs of five pairs of cisplatin-sensitive and cisplatin-resistant ovarian cancer tissues, Zhao et al. (86) found that CDR1as was significantly downregulated in cisplatin-resistant tissues. Mechanism studies confirmed that CDR1as can regulate the sensitivity of ovarian cancer to cisplatin through the miR-1270/SCAI signaling pathway and promote ovarian cancer development. In addition, circRNAs derived from fusion genes have been shown to play a special role in cancers. Recent studies have demonstrated that chromosomal translocations in cancer could not only encode oncogenic fusion proteins but also generate circRNAs. This kind of fusion circRNA (f-circRNA) is unique to cancer and may play an important role in tumorigenesis. F-circRNAs were first identified in a study on leukemia, in which F-circPR and F-circM9 (derived from PML-RARα and MLL-AF9 fusion genes, respectively) were found to promote cellular proliferation, cell viability, and drug resistance (87). In addition, F-circEA-2a, derived from the EML4-ALK fusion gene in NSCLC, is located mainly in the cytoplasm and can promote cell migration and invasion (88). The tumor-suppressive effect of circFAT1 (e2) in GC can simultaneously arise through the cytoplasmic circFAT1 (e2)/miR-548g/RUNX1 axis and the nuclear circFAT1 (e2)/YBN1 regulatory network (89). Thus, the mechanism of circRNAs in vivo is very complicated, and our current knowledge of this process is only nascent. Additional studies are listed in Table 2.

circRNAs AS BIOMARKERS IN CANCER
CircRNAs have a covalently closed circular structure, which increases their resistance to exonuclease digestion and their accumulation in body fluids and tissues (131, 132). In addition, circRNAs are often expressed in a tissue- and developmental stage-specific manner. The properties of circRNAs have inspired numerous studies on their application as promising biomarkers in cancer.

Diagnostic Biomarkers

circRNAs in Tissues
Wei et al. (114) found that circ-CDYL and its target genes (HDGF and HIF1AN) were highly expressed in Barcelona Clinic Liver Cancer (BCLC) stages 0 and A of HCC. Their sensitivity and specificity as combined biomarkers were higher than those of alpha-fetoprotein (AFP) in the early stage of HCC. These results indicated that a panel combining circ-CDYL with HDGF and HIF1AN could be used as a monitoring indicator for early HCC or high-risk populations. In addition, Zhong et al. (133) detected highly expressed CDR1as in nasopharyngeal carcinoma (NPC) biopsy samples. However, unfortunately, current methods for detecting circRNAs in tissue are complex and invasive, which greatly limit their roles in the early diagnosis and screening of cancer.

circRNAs in Peripheral Blood
Numerous studies have confirmed that circRNAs can be stably enriched in peripheral blood, urine, and saliva. Therefore, circRNAs could become suitable biomarkers for liquid biopsy. Recently, a study on the use of plasma circRNAs in the diagnosis of hepatitis B virus (HBV)-associated HCC was published (134). This study included 1,195 plasma samples, which were divided into a training set and two validation sets. The researchers found that the plasma expression levels of hsa_circ_000976, hsa_circ_0007750, and hsa_circ_0139897 in HCC patients were significantly higher than those in healthy controls and patients with chronic hepatitis B or HBV-related liver cirrhosis. They also designed an HCC prediction model named CircPanel through binary logistic regression analysis. CircPanel showed higher sensitivity and specificity (both higher than 80%) than AFP level for distinguishing HCC patients from controls. Notably, CircPanel can also diagnose AFP-negative HCC and AFP-negative small HCC (solitary, diameter ≤3 cm) with high diagnostic accuracy. In another study, Lin et al. (135) found that the plasma levels of circ-CCDC66, circ-ABCC1, and circ-STIL were significantly decreased in CRC patients compared with controls. The combination of these three circRNAs had a sensitivity of 64.4% and 85.2%, respectively, for diagnosing CRC. Notably, f-circRNAs derived from fusion genes are generally cancer-specific and thus have high specificity in diagnosing cancer, which is a unique advantage for tumor biomarkers. Tan et al. (136) reported a fusion circRNA named F-circEA derived from an EML4-ALK fusion gene that was positively expressed in five of six NSCLC patients with EML4-ALK translocation. F-circEA also exists specifically in the plasma of EMLA4-ALK-positive NSCLC patients.

circRNAs in Exosomes
Exosomal circRNAs have received gradually increasing attention in recent years. Li et al. (137) identified more than 1,000 circRNAs in human serum exosomes for the first time and suggested that these circRNAs could distinguish between colon cancer patients and healthy controls. Pan et al. (138) used qRT-PCR to detect hsa-circ_0004771 in circulating exosomes from 170 patients and 45 healthy controls and confirmed that hsa-circ_0004771 could clearly distinguish between patients with stage I/II CRC and...
| Cancer type | CircRNA | Mechanism | Target | Expression in cancer | Function | References |
|------------|---------|-----------|--------|---------------------|----------|------------|
| Lung cancer | hsa_circ_0007059 | MRNA sponge | miR-378/Wnt/β-catenin | Down | Inhibit cell proliferation and EMT, promote apoptosis | (90) |
| | hsa_circ_103809 | MRNA sponge | miR-4302/ZNF121/ERK1 | Up | Promote cell proliferation and invasion | (91) |
| | circRNA 100146 | MRNA sponge | miR-361-3p, miR-615-5p, SF3B3 | Up | Inhibit cell proliferation and invasion, promote apoptosis | (92) |
| | circPTK2 | MRNA sponge | miR-429, miR-200b-3p/ TGF-β | Down | Inhibit EMT and metastasis | (93) |
| | circHIPK3 | MRNA sponge | miR124-3p/STAT3/PRKAA and AMPKa | Up | Promote cell proliferation, migration and invasion, inhibit macroautophagy and autophagy | (94) |
| | cESRP1 | MRNA sponge | miR-93-5p/CDKN1A | Down | Increase chemotherapy sensitivity | (95) |
| Colorectal cancer | cMras | MRNA sponge | miR-567/PTPRQ | Down | Inhibit LUAD growth and metastasis | (96) |
| | circNSUN2 | Protein scaffolds | IGF2BP2/ HMGA2 | Up | Promote liver metastasis and cells invasion | (97) |
| | circACC1 | Protein scaffolds | AMPK | Up | Promote cell proliferation | (98) |
| | circCCDC66 | MRNA sponge | miR-33b, miR-93 | Up | Promote cell proliferation, migration, and metastasis | (99) |
| | circHIPK3 | MRNA sponge | miR-7/ FAK, IGF1R, EGFR, YY1 | Up | Promote cell proliferation, migration and invasion, inhibit cell apoptosis | (100) |
| | circPPP1R12A | Translation template | circPPP1R12A-73aa/Hippo-YAP | Up | Promote cell proliferation, migration and invasion | (101) |
| | circLgr4 | Translation template | circLgr4-peptide/Wnt/β-catenin | Up | Promote colorectal cancer stem cells (CSCs) self-renewal, colorectal tumorigenesis and invasion | (102) |
| | hsa_circ_0053277 | MRNA sponge | miR-2467-3p/MMP14 | Up | Promote cell proliferation, migration and invasion, inhibit apoptosis | (103) |
| | hsa_circ_0001178 | MRNA sponge | miR-382, miR-587, miR-616/2EB1 | Up | Promote cell proliferation, migration and invasion, inhibit cell apoptosis | (104) |
| Gastric cancer | circNRIP1 | MRNA sponge | miR-149-5p/AKT1-mTOR | Up | Promote cell proliferation, migration, invasion | (105) |
| | circPSMC3 | MRNA sponge | miR-296-5p/PTEN | Down | Inhibit the tumorigenesis in vivo and in vitro | (106) |
| | circ-DNCON | Protein scaffolds | NURF/SOX4 | Up | Promote cell proliferation, migration and invasion, inhibit apoptosis | (107) |
| | circYAP1 | MRNA sponge | miR-3067-3p/27 Kip1 | Down | Inhibit cell growth and invasion in vitro and in vivo | (108) |
| | circLARP4 | MRNA sponge | miR-424/LATS1 | Down | Inhibit cell proliferation and invasion | (109) |
| | circFat1-2 | MRNA sponge | miR-548g/RUNX1 YBX1 | Down | Promote cell proliferation, migration, and invasion | (110) |
| | circDLST | MRNA sponge | miR-502-5p/NFAS/MEK1/ERK1/2 | Up | Promote the tumorigenesis and metastasis | (111) |
| | circ-HuR | Protein scaffolds | CNBP/HuR | Down | Inhibit cell growth, invasion, and metastasis | (112) |
| | circCSBPPL10 | MRNA sponge | miR-136-5p/WNT2 | Up | Promote cell growth, migration, and invasion | (113) |
| | circKIF4A | MRNA sponge | cirKIF4A-miR-375-KIF4A | Up | Promote cell proliferation and migration | (114) |
| | circERCh1 | Protein scaffolds | FL1/TET1 | Up | Enhance invasiveness of breast cancer cells | (115) |
| | circ-Dirn1 | Protein scaffolds | p53/AUF1 | Up | Promote the proliferative and survival capacities of breast cancer cells by stimulating cellular autophagy | (116) |
| | circANKS1B | MRNA sponge | miR-148a-3p, miR-152-3p/USF1/TGF-β1/Smad | Up | Promote breast cancer invasion and metastasis | (117) |
| | circEPST1 | MRNA sponge | miR-4753, 6809/BCL11A | Up | Promote cell proliferation, inhibit apoptosis | (118) |
| | circIARK | MRNA sponge | miR-3607/Foxc1 | Up | Promote cell migration, invasion and metastasis | (119) |
| | circAGFG1 | MRNA sponge | miR-195-5p/ CON1 | Up | Promote triple-negative breast cancer (TNBC) cell proliferation, mobility and invasion as well as tumorigenesis and metastasis in vivo | (120) |
| | circFBXW7 | Translation template | FBXW7-185aa/c-Myc | Down | Inhibit proliferation and migration abilities of TNBC cells | (121) |
| | cSMARCA5 | MRNA sponge | miR-17-3p, miR-181b-5p/TIMP3 | Down | Inhibit cell proliferation and migration of HCC cells | (122) |
| | circMT01 | MRNA sponge | miR-92-2p21 | Down | Promote tumor growth | (123) |
| | circ-CDYIL | MRNA sponge | miR-892a/HDGF, miR-328-3p/HIF1AN | Up | Promote cell proliferation, migration and invasion | (124) |
TABLE 2 | Continued

| Cancer type | CircRNA | Mechanism | Target | Expression in cancer | Function | References |
|-------------|---------|-----------|--------|---------------------|----------|------------|
| Ovarian cancer | circPLEKH3 | MRNA sponge | miR-9/BRCAl/DNAJB6/KLF4/AKT1 | Down | Inhibit cell growth, migration and EMT | (118) |
| | hsa_circ_0061140 | MRNA sponge | miR-370/FOXO1 | Up | Promote cell proliferation and migration | (119) |
| | hsa_circ_0051240 | MRNA sponge | miR-637/KLK4 | Up | Promote cell proliferation, migration and invasion | (120) |
| | circWHSC1 | MRNA sponge | miR-145/MUC1 | Up | Promote cell proliferation, migration and invasion, inhibit cell apoptosis | (121) |
| Prostate cancer | circFoxo3 | Modulators of transcription | Foxo3 | Down | Inhibit prostate cancer viability and EMT | (26) |
| | circZNF609 | MRNA sponge | miR-186-5p/YAP1/AMPK | Up | Promote growth, migration and invasion | (122) |
| | circ0005276 | Modulators of transcription | FUS/XIAP | Up | Promote cell proliferation, migration and EMT | (123) |
| Pancreatic cancer | circZMYM2 | MRNA sponge | miR-335-5p/JMJD2C | Up | Promote cell proliferation and invasion, inhibit cell apoptosis | (124) |
| | hsa_circ_0000977 | MRNA sponge | miR-874-3p/PLK1 | Up | Promote pancreatic cancer growth | (125) |
| | circ-ASH2L | MRNA sponge | miR-34a/Notch 1 | Up | Promote tumor invasion, proliferation and angiogenesis | (126) |
| Glioblastoma | circNT5E | MRNA sponge | miR-422a | Up | Promote cell proliferation, migration and invasion | (127) |
| | circMMP9 | MRNA sponge | miR-124/CDK4/AURKA | Up | Promote cell proliferation, migration and invasion | (128) |
| Bladder cancer | BCRC-3 | MRNA sponge | miR-182-5p/p27 | Down | Inhibit cell proliferation | (73) |
| Esophageal squamous cell carcinoma | cirs-7 | MRNA sponge | miR-7-HOXB-13/NF-xB/p65 | Up | Inhibit cell proliferation, migration and invasion | (129) |
| Gallbladder cancer | circERBB2 | Protein scaffolds | PA2G4/TIF1A | Up | Modulate ribosomal DNA transcription and cell proliferation | (130) |

*circRNA, circular RNA; EMT, epithelial–mesenchymal transition; HCC, hepatocellular carcinoma; LUAD, lung adenocarcinoma.*

those with benign intestinal diseases. Li et al. (139) detected high expression of circ-PDE8A in liver-metastatic pancreatic ductal adenocarcinoma (PDAC) tissues, and this characteristic was confirmed to be closely related to lymphatic infiltration, T status, and TNM stage. Circ-PDE8A is an independent risk factor for the survival of PDAC patients. Further research confirmed the presence of circ-PDE8A-rich exosomes secreted from tumor cells in the plasma of PDAC patients. Similarly, circ-PDE8A in plasma exosomes may also be a diagnostic and prognostic marker for PDAC.

circRNAs in Other Body Fluids

The use of circRNAs in other body fluid samples has also been studied. For example, gastric juice examination is a highly organ-specific test for the diagnosis of gastric diseases. Shao et al. (140) explored the feasibility of hsa_circ_0014717 in gastric juice as a biomarker for screening patients with GC. The expression of hsa_circ_0014717 in gastric juice from 38 healthy people, 30 patients with gastric ulcers, 15 patients with chronic atrophic gastritis, and 39 patients with GC was measured by qRT-PCR. Hsa_circ_0014717 was significantly downregulated in patients with chronic atrophic gastritis compared with healthy controls, suggesting the potential utility of hsa_circ_0014717 in gastric juice as a biomarker for screening high-risk populations for GC. In addition, saliva is a body fluid used for disease research due to its convenient and noninvasive sampling method. Bahn et al. (141) detected and verified the presence of circRNAs in cell-free saliva, which suggested a new direction for the application of circRNAs as biomarkers. Moreover, Chen et al. (142) detected highly expressed circPRMT5 in exosomes isolated from urine samples from patients with urothelial carcinoma of the bladder (UCB). Additional studies are listed in Table 3.

Prognostic Biomarkers

circRNAs Predict Patient Survival

CircRNAs have wide application prospects in monitoring the treatment efficacy and assessing the prognosis of cancer. By using RNA-seq to identify circRNAs related to HCC progression, Qiu et al. (156) determined that circADAMTS13 was significantly downregulated in HCC tissues compared
TABLE 3 | CircRNAs as diagnostic biomarkers in cancer.

| Cancer type       | CircRNA                  | Source  | Cohort size | Expression in cancer | AUC  | Sensitivity % | Specificity % | Relationship with other biomarkers | References |
|-------------------|--------------------------|---------|-------------|----------------------|------|---------------|---------------|-------------------------------------|------------|
| HCC               | circZKSCAN1              | Tissue  | 102         | Down                 | 0.834| 82.2          | 72.4          | –                                   | (143)      |
|                   | circ_104075              | Tissue  | 89          | Down                 | 0.973| 96.0          | 98.3          | Perform better than DANCR, HULC, miR-223, miR-21, UCA1, AFP, DCP, and AFPL3-1 in detecting HCC from hepatitis and cirrhosis, respectively | (144)      |
|                   | circSMARCA5              | Plasma  | 489         | Down                 | 0.938| –             | –             | When combined with AFP, the AUC increased to 0.903 and 0.858 in detecting HCC from hepatitis and cirrhosis, respectively | (145)      |
|                   | hsa_circ_0000976, hsa_circ_0007750, and hsa_circ_0139897 | Plasma  | 1195        | Up                   | 0.863| –             | –             | Perform better than AFP in diagnosing HCC and SmallHCC | (134)      |
| Gastric cancer    | hsa_circ_0000745         | Plasma  | 120         | Down                 | 0.683| 85.5          | 45.0          | Perform better than AFP in diagnosing early stage of HCC | (114)      |
|                   | hsa_circ_0000520         | Tissue  | 56          | Down                 | 0.6129| 53.57         | 85.71         | –                                   | (147)      |
|                   | hsa_circ_0000520         | Plasma  | 62          | Up                   | 0.8967| 82.35         | 84.44         | Associated with CEA | (147)      |
|                   | hsa_circ_0014717         | Tissue  | 96          | Down                 | 0.696 | 59.38 | 81.25 | Associated with CEA and CA19-9 | (140)      |
|                   | hsa_circ_000096          | Tissue  | 101         | Down                 | 0.82 | –             | –             | When combined with hsa_circ_002509, the AUC increased to 0.91, while the sensitivity and specificity changed to 0.800 and 0.633 | (148)      |
| Lung cancer       | hsa_circ_0013958         | Tissue  | 49          | Up                   | 0.815 | 75.5 | 79.6 | –                                   | (149)      |
|                   | hsa_circ_0075930         | Tissue  | 92          | Up                   | 0.756 | 76.2 | 72.1 | –                                   | (150)      |
|                   | circRNA_102231           | Tissue  | 57          | Up                   | 0.897 | 81.2 | 88.7 | –                                   | (151)      |
|                   | circFARSA                | Plasma  | 100         | Up                   | 0.71  | –             | –             | –                                   | (71)       |
| Colorectal cancer | circ-CCDC66, circ-ABCC1 and circ-STIL | Plasma  | 106         | Down                 | 0.78  | 64.4 | 85.2 | When combined with CEA and CA19-9, the AUC increased to 0.855 in detecting CRC | (135)      |
|                   | circVAPA                 | Plasma  | 103         | Up                   | 0.724 | –             | –             | –                                   | (152)      |
|                   | circITGA7                | Tissue  | 69          | Down                 | 0.8791| 92.75 | 66.67 | –                                   | (153)      |
|                   | hsa-circ-0004771         | Circulating exosome | 215 | Up                   | 0.88  | 80.91 | 82.86 | –                                   | (138)      |
| Pancreatic cancer | circ-LDLRAD3             | Plasma  | 62          | Up                   | 0.67  | 57.38 | 70.49 | When combined with CA19-9, the AUC increased to 0.87 and the sensitivity and specificity were 0.8033 and 0.9355, respectively | (154)      |
| Osteosarcoma      | circPVT1                 | Serum   | 90          | Up                   | 0.871 | –             | –             | Perform better than ALP and LDH | (155)      |

AFP, alpha-fetoprotein; circRNA, circular RNA; HCC, hepatocellular carcinoma.

with matched nontumor tissues. Moreover, its expression was positively associated with recurrence-free survival (RFS). Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of circADAMTS13 in HCC patients, and the area under ROC curve (AUC) was 0.987. He et al. (157) determined that circGFRA1 was significantly upregulated in triple-negative breast cancer via circRNA microarray analysis. In addition, Kaplan–Meier survival analysis showed that upregulation of circGFRA1 was associated with poorer clinical survival. CircHIPK3 is significantly upregulated in CRC tissues and cell lines and is associated with the T status of tumors, lymph node and distant metastasis, and advanced clinical stage (97). High expression of circHIPK3 in CRC is an independent prognostic factor for poor overall survival (OS). Compared with paired nontumorous tissues, GC tissues exhibit significant downregulation of hsa_circ_0000096; moreover, the AUC increased from 0.82 to 0.91 when hsa_circ_0000096 was combined with hsa_circ_002509 (148). Analysis of 90 paired...
### TABLE 4 | CircRNAs as prognostic biomarkers in cancer (cohort size ≥ 50).

| Cancer type             | CircRNA      | Source     | Cohort size | Expression in cancer | Clinical significance                                                                                                                                                                                                                                                                     | References |
|-------------------------|--------------|------------|-------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Hepatocellular carcinoma | circADAMTS13 | Tissue     | 102         | Down                 | Negatively associated with tumor size, BCLC stage; Positively associated with RFS                                                                                                                                                         | (156)      |
|                         | SCD-circRNA 2 | Tissue     | 151         | Up                   | Negatively associated with RFS and OS; Positively associated with RFS                                                                                                                                                                  | (162)      |
|                         | circRNA_100338 | Tissue     | 80          | Up                    | Negatively associated with OS; Positively associated with TNM stage, vascular invasion and lung metastasis                                                                                                                                     | (163)      |
|                         | circRNA 101368 | Tissue     | 51          | Up                    | Negatively associated with OS; Positively associated with distant metastasis, TNM stage, tumor size                                                                                                                                       | (164)      |
|                         | circ-10720    | Tissue     | 381         | Up                    | Negatively associated with survival; Positively associated with clinical stage, pathology grade, AFP level and hepatitis B markers                                                                                                            | (165)      |
|                         | circSMARCA5   | Tissue     | 197         | Down                 | Negatively associated with TNM stage, tumor invasion and tumor size; Positively associated with tumor differentiation                                                                                                                     | (145)      |
| Gastric cancer          | circLARP4     | Tissue     | 80          | Down                 | Negatively associated with tumor size and lymphatic metastasis; Positively associated with OS                                                                                                                                           | (104)      |
|                         | hsa_circ_0001368 | Tissue     | 68          | Down                 | Positively associated with prognosis                                                                                                                                                                                                  | (166)      |
|                         | circPV1       | Tissue     | 187         | Up                    | Positively associated with OS and DFS                                                                                                                                                                                                  | (22)       |
|                         | circNRIP1     | Tissue     | 80          | Up                    | Negatively associated with OS and DFS; Positively associated with tumor size and lymphatic invasion                                                                                                                                       | (76)       |
|                         | circ-KIAA1244 | Plasma     | 87          | Down                 | Negatively associated with OS; Positively associate with TNM stage and lymphatic metastasis, and poor overall survival time                                                                                                                  | (167)      |
| Lung cancer             | ciRS-7        | Tissue     | 149         | Up                    | Positively associate with cisplatin resistance                                                                                                                                                                                           | (161)      |
|                         | circ-PRMT5    | Tissue     | 90          | Up                    | Negatively associated with OS and progression-free survival; Positively associated with tumor size, lymph node metastasis and TNM stage                                                                                                        | (169)      |
|                         | circPTK2      | Tissue     | 73          | Down                 | Positively associated with metastatic NSCLC Tissues                                                                                                                                                                                       | (93)       |
|                         | circ_0016760  | Tissue     | 83          | Up                    | Negatively associated with OS; Positively associated with TNM stage and lymph node metastasis                                                                                                                                             | (170)      |
| Breast cancer           | hsa_circ_0000064 | Tissue   | 50          | Up                    | Positively associated with TNM stage and lymphatic metastasis                                                                                                                                                                           | (171)      |
|                         | hsa_circRNA_002178 | Tissue   | 70          | Up                    | Negatively associated with survival                                                                                                                                                                                                   | (172)      |
|                         | circ_0005230  | Tissue     | 76          | Up                    | Negatively associated with OS; Positively associated with tumor size, TNM stage and lymph node metastasis                                                                                                                             | (173)      |
|                         | circKIF4A     | Tissue     | 240         | Up                    | Negatively associated with survival                                                                                                                                                                                                    | (108)      |
|                         | circGFRA1     | Tissue     | 51          | Up                    | Negatively associated with survival                                                                                                                                                                                                    | (157)      |
|                         | CircCCDC66    | Tissue     | 229         | Up                    | Negatively associated with OS                                                                                                                                                                                                            | (96)       |
|                         | circHIPK3     | Tissue     | 178         | Up                    | Negatively associated with OS; Positively associated with metastasis and advanced clinical stage                                                                                                                                            | (97)       |
|                         | circVAPA      | Tissue     | 60          | Up                    | Positively associated with lympho-vascular invasion, depth of invasion, lymph node metastasis, distant metastasis and TNM stage                                                                                                              | (152)      |
| Colorectal cancer       | circMTO1      | Tissue     | 117         | Up                    | Negatively associated with OS and DFS; Positively associated with lymph node metastasis                                                                                                                                                   | (174)      |
|                         | cTFRC         | Tissue     | 220         | Up                    | Negatively associated with prognosis; Positively associated with tumor grade and T stage                                                                                                                                                   | (175)      |
| Bladder cancer          | circ-IARS     | Tissue     | 79          | Up                    | Negatively associated with survival; Positively associated with liver metastasis, vascular invasion, and TNM stage                                                                                                                          | (176)      |
|                         | circ-PDE8A    | Plasma exosomes | 56       | Up                    | Negatively associated with survival; Positively associated with duodenal invasion, vascular invasion, T factor and TNM stage                                                                                                                  | (139)      |
| Pancreatic cancer       | circ-IARS     | Tissue     | 86          | Down                 | Positively associated with OS and RFS                                                                                                                                                                                                  | (118)      |
|                         | circWHSC1     | Tissue     | 92          | Up                    | Negatively associated with differentiation                                                                                                                                                                                               | (121)      |
| Ovarian cancer          | circPLEKHM3   | Tissue     | 86          | Down                 | Positively associated with OS and RFS                                                                                                                                                                                                  | (118)      |
|                         | circWHSC1     | Tissue     | 92          | Up                    | Negatively associated with differentiation                                                                                                                                                                                               | (121)      |
| Osteosarcoma            | hsa_circ_0081001 | Tissue   | 82          | Up                    | Negatively associated with clinical outcome                                                                                                                                                                                             | (177)      |
| Nasopharyngeal cancer   | CDR1as       | Biopsy     | 64          | Up                    | Positively associated with survival                                                                                                                                                                                                     | (133)      |
| Gioma                   | circ_0034642  | Tissue     | 68          | Up                    | Negatively associated with survival; Positively associated with tumor size and advanced WHO grade                                                                                                                                        | (178)      |

AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; circRNA, circular RNA; DFS, disease-free survival; OS, overall survival; RFS, recurrence-free survival.
samples of NSCLC and adjacent normal tissues showed that hsa_circ_0014130 was significantly upregulated in NSCLC and was found to be related to tumor size, TNM stage, and lymphatic metastasis (158). ROC analysis indicated that hsa_circ_0014130 might be a prognostic biomarker in NSCLC.

In addition to identifying the differential expression of hsa_circ_002059 in GC and adjacent tissues, Li et al. (159) also found that the expression levels of hsa_circ_002059 in 36 pairs of matched plasma samples from preoperative and postoperative GC patients were significantly different. Considering that circRNAs can be secreted into the tumor microenvironment and the circulatory system by tumor cells, it is reasonable to speculate that circRNAs can be used as biomarkers to evaluate the tumor-bearing status of patients. As mentioned above, circHIPK3 can regulate the autophagy process in lung cancer through the miR124-3p–STAT3–PRKAA/AMPKa axis (85). In addition, researchers found that the ratio (C.L ratio) of circHIPK3 to linear HIPK3 (linHIPK3) can reflect the level of autophagy in cells—a higher C.L ratio indicates a lower level of autophagy and poorer prognosis.

circRNAs Predict Not Only Tumor Metastasis but Also Drug Resistance

Recent studies have also reported that circRNAs can predict tumor metastasis and drug resistance. Xu et al. (160) analyzed the circRNA expression profile of three pairs of CRC patients with or without liver metastasis. Further verification demonstrated that circRNA_0001178 and circRNA_0000826 were significantly upregulated in metastatic CRC (CRC-m) tissues. The AUCs were 0.945 for circRNA_0001178 and 0.816 for circRNA_0000826, and both two circRNAs could differentiate liver metastases from CRC. CircASAP1 is highly expressed in the tissues of HCC patients with pulmonary metastases after curative resection (77), and its expression is positively correlated with the levels of CSF-1, MAPK1, and CD68+ tumor-associated macrophage. Patients with high circASAP1 expression tend to have relatively low OS and high recurrence rates. Therefore, circASAP1 can be used as a prognostic indicator for HCC.

In addition, cisplatin is one of the main chemotherapeutic drugs used to treat GC. Huang et al. (161) analyzed the correlation between the clinical efficacy of cisplatin and circRNA expression in 105 cisplatin-treated patients, and they found that the expression of circAKT3 in cisplatin-resistant patients was higher than that in cisplatin-sensitive patients. CircAKT3 is an effective predictive biomarker for cisplatin resistance in GC patients (AUC = 0.91). Confirmation of the relationships between circRNA expression and drug sensitivity would provide guidance for reasonable clinical medication and thus improve patient prognosis. Additional studies are listed in Table 4.

CONCLUSIONS AND PERSPECTIVES

As the understanding of circRNAs has increased, their perception by the scientific community has changed dramatically. CircRNAs are not “splicing noise” but rather a class of structurally stable RNA molecules with multiple biological functions. circRNAs are generally derived from back-splicing of pre-mRNA and are widely expressed across biological systems.

The relationship between circRNAs and cancer has recently become an area of research interest. Numerous circRNAs are dysregulated and play regulatory roles in the development of cancer. Several examples of research on the roles of circRNAs in cancer are given above. In summary, circRNAs, through various signaling pathways, can participate in and affect processes related to cell proliferation, migration and invasion, apoptosis, autophagy, and drug resistance, as well as others. This capacity has inspired researchers to consider the therapeutic possibilities of targeting circRNAs and their associated pathways. In addition, researchers have also tried to synthesize artificial circRNAs for disease treatment. For example, an artificial circRNA with eight miRNA-122 binding sites was used to competitively bind to miRNA-122, which is required for the hepatitis C virus (HCV) life cycle, thereby inhibiting the propagation of HCV, with an efficiency comparable to that of the anti-miR drug miravirsen (179). This study proposed the idea that engineered circRNAs could be used for disease-specific treatments, similar to targeted drugs; however, this idea is far from clinical translation. Due to their stable structure, conservative sequence, and specific expression pattern, circRNAs have the potential to be used as biomarkers for cancer. circRNAs have wide clinical application prospects—from diagnostic assessments to predicting patient prognosis and treatment response. However, most related studies have been single-center and retrospective works.

The study of circRNAs is just beginning, and the mechanism of circRNA biogenesis is not well understood. Even though a few circRNAs have been functionally characterized, our understanding of circRNAs remains incomplete. In addition to the identified functions as miRNA sponges, protein scaffolds, translation templates, and transcriptional regulators, other mechanisms are awaiting discovery, and the cooperation and the relative importance of these mechanisms cannot be evaluated at present. In addition, the transport and degradation mechanisms of circRNAs are poorly understood. Therefore, much work remains to be done. The discovery of circRNAs has undoubtedly enriched the content of RNA regulatory networks and has offered new approaches for the development of clinically translatable diagnostic/prognostic biomarkers and therapeutic targets for cancer.

AUTHOR CONTRIBUTIONS

JL, XZ, and MY collected literatures and wrote the manuscript. HL contributed to writing design and revised the manuscript. All authors read and approved the final manuscript.

FUNDING

This review was funded by the National Natural Science Foundation of China (81772620), National Key R&D Program of China (2018ZX09201015), and Tianjin Science and Technology Major Project of Chronic Diseases Prevention and Control (17ZXMXFSY00130).
REFERENCES

1. Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. (2015) 12:381–8. doi: 10.1089/rna.2015.1020271

2. Zhang XO, Wang HB, Zhang Y, Lu X, Chen LL, Yang L. Complementary sequence-mediated exon circularization. Cell. (2014) 159:134–47. doi:10.1016/j.cell.2014.09.001

3. Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci USA. (1976) 73:3852–6. doi:10.1073/pnas.73.11.3852

4. Kos A, Dijkema R, Arnberg AC, van der Meide PH, Schellekens H. The hepatitis delta (delta) virus possesses a circular RNA. Nature. (1986) 323:558–60. doi:10.1038/323558a0

5. Arnberg AC, Van Ommen GJ, Grivell LA, van Bruggen EF, Borst P. Some yeast mitochondrial RNAs are circular. Cell. (1980) 19:313–9. doi:10.1016/0092-8674(80)90505-X

6. Danan M, Schwartz S, Edelheit S, Sorek R. Transcriptome-wide discovery of circular RNAs in Archaea. Nucleic Acids Res. (2012) 40:3131–42. doi:10.1093/nar/gkr1009

7. Houseley JM, Garcia-Casado Z, Pascual M, Paricio N, O’Dell KM, Moncckton DG, et al. Noncanonical RNAs from transcripts of the Drosophila muscleblind gene. J Heredity. (2006) 97:253–60. doi:10.1093/jhered/es037

8. Capel B, Swain A, Nicolas S, Hacker A, Walter M, Koopman P, et al. Circular transcripts of the testis-determining gene Sry in adult mouse testis. J Cell Biol. (1993) 129:1019–30. doi:10.1083/jcb.129.3.90279-Y

9. Nigro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, Monckton DG, et al. Noncanonical RNAs from transcripts of the Drosophila sequence-mediated exon circularization. J Am Coll Cardiol. (2014) 63:2177–87. doi:10.1016/j.jacc.2014.01.050

10. Lukwi WJ. Circular RNA (circRNA) in Alzheimer’s disease (AD). Front Genet. (2013) 4:307. doi:10.3389/fgene.2013.00307

11. Shan K, Liu C, Liu BH, Chen X, Dong R, Liu X, et al. Circular noncoding RNA HIPK3 mediates retinal vascular dysfunction in diabetes mellitus. Circulation. (2017) 136:1629–42. doi:10.1161/CIRCULATIONAHA.117.029004

12. Wong DK, Yuen MF, Pooy KN, Yuen JC, Fung J, Lai CL. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol. (2006) 45:553–9. doi:10.1016/j.jhep.2006.05.014

13. He J, Xie Q, Xu H, Li J, Y. Circular RNAs and cancer. Cancer Lett. (2017) 396:138–44. doi:10.1016/j.canlet.2017.03.027

14. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNA molecules. Cell. (2013) 153:131–43. doi:10.1016/j.cell.2013.09.001

15. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are abundant, conserved, and dynamically expressed. Genes Dev. (2013) 27:155–60. doi:10.1101/gad.205958.112

16. Ivanov A, Memczak S, Wyler E, Torti F, Porath HT, Orejuela MR, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. Nucleic Acids Res. (2015) 43:13711–22. doi:10.1093/nar/gkv1021

17. Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA. (2014) 20:1829–42. doi:10.1261/rna.047126.114

18. Conn SJ, Pillman KA, Toubia J, Conn VM, Salmonakis M, Phillips CA, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. (2015) 160:1125–34. doi:10.1016/j.cell.2015.02.014

19. Li X, Liu CX, Xue W, Zhang Y, Jiang S, Yin QF, et al. Coordinated circRNA biogenesis and function with NF90/NF110 in viral infection. Mol Cell. (2017) 67:214–27.e7. doi:10.1016/j.molcel.2017.05.023

20. Errichelli L, Dini Modigliani S, Laneve P, Colantoni A, Legnini I, Caputo D, et al. FUS affects circular RNA expression in murine embryonic stem cell-derived motor neurons. Nat Commun. (2017) 8:14741. doi:10.1038/s41467-017-04147-0

21. Ivanov A, Memczak S, Wyler E, Torti F, Forth AT, Orejuela MR, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. (2015) 10:170–7. doi:10.1016/j.celrep.2014.12.019

22. Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, et al. Circular RNA identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett. (2017) 388:208–19. doi:10.1016/j.canlet.2016.12.006

23. Lukiw WJ. Circular RNA (circRNA) in Alzheimer’s disease. Front Mol Neurosci. (2017) 10:170. doi:10.3389/fnmol.2017.00170

24. Westholm JO, Miura P, Olson S, Shenker S, Joseph B, Sanfilippo P, et al. Circular RNA and sequence-mediated exon circularization. Nucleic Acids Res. (2016) 44:1370–83. doi:10.1093/nar/gkw152

25. Guo J, Ge J, Wang B, Zhang Q, Zhang J, Yang L, et al. Circular RNAs are abundant, conserved, and dynamically expressed. Genes Dev. (2013) 58:870–85. doi:10.1101/gad.208955.115

26. Guo J, Ge J, Wang B, Zhang Q, Zhang J, Yang L, et al. Circular RNAs are abundant, conserved, and dynamically expressed. Genes Dev. (2013) 58:870–85. doi:10.1101/gad.208955.115

27. Westholm JO, Miura P, Olson S, Shenker S, Joseph B, Sanfilippo P, et al. Genome-wide analysis of drosophila circular RNAs reveals their structural and sequence properties and age-dependent neural accumulation. Cell Rep. (2014) 9:1966–80. doi:10.1016/j.celrep.2014.10.062

28. You X, Vlakovic I, Babic A, Will T, Epstein I, Tushev G, et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nat Neurosci. (2015) 18:603–10. doi:10.1038/nn.3975
44. Szabo L, Morey R, Palpant NJ, Wang PL, Afari N, Jiang C, et al. Statistically based splicing detection reveals neural enrichment and tissue-specific induction of circular RNA during human fetal development. Genome Biol. (2015) 16:126. doi: 10.1186/s13059-015-0690-9

45. Hanan M, Soreq H, Kadener S. Circular RNAs in the brain. RNA Biol. (2017) 14:1028–34. doi: 10.1080/15476286.2017.1325398

46. Gruner H, Cortes-Lopez M, Cooper DA, Bauer M, Miura P. Circular RNA accumulation in the aging mouse brain. Sci Rep. (2016) 6:38907. doi: 10.1038/srep38907

47. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. (2008) 40:1413–5. doi: 10.1038/ng.259

48. Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Bachleitner-Hofmann T, et al. Correlation of circular RNA abundance with proliferation–exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. Sci Rep. (2015) 5:8057. doi: 10.1038/srep08057

49. Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. Circular RNA isoform isolation method (RPAD) reveals vast collection of intronic circular RNAs. Nucleic Acids Res. (2017) 45:e116. doi: 10.1093/nar/gkx297

50. Jakobi T, Dieterich C. Computational approaches for circular RNA analysis. Wiley Interdiscip Rev RNA. (2019) 10:e1528. doi: 10.1002/wrna.1528

51. Zeng X, Lin W, Guo M, Zou Q. A comprehensive overview and evaluation of circular RNA detection tools. PLoS Comput Biol. (2013) 9:e1003540. doi: 10.1371/journal.pcbi.1003540

52. Xia S, Feng J, Lei L, Hu J, Xia L, Wang J, et al. Comprehensive characterization of tissue-specific circular RNAs in the human and mouse genomes. Briefings Bioinform. (2017) 18:984–92.

53. Chen X, Han P, Zhou T, Guo M, Song X, Li Y. circRNADb: A comprehensive database for human circular RNAs with protein-coding annotations. Sci Rep. (2016) 6:34985. doi: 10.1038/srep34985

54. Zheng LL, Li JJ, Wu J, Sun WJ, Liu S, Wang ZL, et al. DeepBase v2.0: identification, expression, and function of small RNAs, lncRNAs and circular RNAs from deep-sequencing data. Nucleic Acids Res. (2016) 44:D196–202. doi: 10.1093/nar/gkv1273

55. Chen X, Han P, Zhou T, Guo M, Song X, Li Y. circRNAdb: A comprehensive database for human circular RNAs with protein-coding annotations. Sci Rep. (2016) 6:34985. doi: 10.1038/srep34985

56. Xia S, Feng J, Lei L, Hu J, Xia L, Wang J, et al. Comprehensive characterization of tissue-specific circular RNAs in the human and mouse genomes. Briefings Bioinform. (2017) 18:984–92.

57. Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. (2016) 13:34–42. doi: 10.1080/15476286.2015.1120865

58. Xia S, Feng J, Chen K, Ma Y, Gong J, Cai F, et al. CScD: a database for cancer-specific circular RNAs. Nucleic Acids Res. (2018) 46:D9295–9. doi: 10.1093/nar/gkx563

59. Gehr S, Das S, Sen R, Basak P, Chakrabarti J. Cric2Traits: a comprehensive database for circular RNA potentially associated with disease and traits. Front Genet. (2013) 4:283. doi: 10.3389/fgene.2013.00283

60. Vo JN, Gesluk M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The landscape of circular RNA in cancer. Cell. (2019) 176:869–81.e13. doi: 10.1016/j.cell.2018.12.021

61. Li S, Li Y, Chen B, Zhao J, Yu S, Tang Y, et al. exoRBase: A database of circular RNA, IncRNA and mRNA in human blood exosomes. Nucleic Acids Res. (2018) 46:D3985–9. doi: 10.1093/nar/gky386

62. Hanan T, Kjemps J, Damgaard CK. Circular RNA and mir-7 in cancer. Cancer Res. (2013) 73:5609–12. doi: 10.1158/0008-5472.CAN-13-1566

63. Abdelmohsen K, Panda AC, Munk R, Grammatikakis I, Dudekula DB, De S, et al. Identification of HuR target circular RNAs uncovers suppression of PARP1 translation by CircPARP1. RNA Biol. (2017) 14:361–9. doi: 10.1080/15476286.2017.1279788

64. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intronic circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. (2015) 22:256–64. doi: 10.1038/nsmb.2959

65. Du WW, Yang W, Chen Y, Wu ZK, Foster FS, Yang Z, et al. Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. Eur Heart J. (2017) 38:1402–12. doi: 10.1093/eurheartj/ehw001

66. Chen RX, Chen X, Xia LP, Zhang JX, Pan ZZ, Ma XD, et al. N(6)-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nat Commun. (2019) 10:6965. doi: 10.1038/s41467-019-12651-2

67. Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, et al. Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis. J Natl Cancer Inst. (2018) 110:304–15. doi: 10.1093/jnci/djx166

68. Jiang C, Xiao L, Peng Y, Song X, Zhang J, et al. Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA1/AMPKalpha signaling in STK11 mutant lung cancer. Autophagy. (2019) 15:1107–16. doi: 10.1080/15548627.2019.1634945

69. Zhao Z, Ji M, Wang Q, He N, Li Y. Circular RNA Cdr1as upregulates SCAI to suppress cisplatin resistance in ovarian cancer via
Circular RNAs in Cancer

Liu et al.

102. Ding L, Zhao Y, Dang S, Wang Y, Li X, Yu X, et al. Circular RNA circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by splicing miR-424-3p and regulating LATS1 expression. Mol Cancer. (2017) 16:151. doi: 10.1186/s12943-017-0719-3

103. Zhang J, Hou L, Liang R, Chen X, Zhang R, Chen W, et al. CircularLST promotes the tumorigenesis and metastasis of gastric cancer by splicing miR-502-5p and activating the NRAS/MEKI/ERK1/2 signaling. Mol Cancer. (2019) 18:80. doi: 10.1186/s12943-019-1015-1

104. Yang F, Hu A, Li D, Wang J, Guo Y, Liu Y, et al. Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation. Mol Cancer. (2019) 18:158. doi: 10.1186/s12943-019-1094-z

105. Wang S, Zhang X, Li Z, Wang W, Li B, Huang X, et al. Circular RNA profile identifies circOSBPL10 as an oncogenic factor and prognostic marker in gastric cancer. Oncogene. (2019) 38:6985–7001. doi: 10.1038/s41388-019-0933-0

106. Zeng K, He B, Yang BB, Xu T, Chen X, Xu M, et al. The prometastasis effect of circANKS1B in breast cancer. Mol Cancer. (2017) 18:160. doi: 10.1186/s12943-018-0914-x

107. Wu J, Jiang Z, Chen C, Hu Q, Fu Z, Chen J, et al. CircIRA3K3 sponges miR-3607 to facilitate breast cancer metastasis. Cancer Lett. (2018) 430:179–92. doi: 10.1016/j.canlet.2018.05.033

108. Yang R, Xing L, Zheng X, Sun Y, Wang X, Chen J. The circular RNA circAGFI1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression. Mol Cancer. (2019) 18:64. doi: 10.1186/s12943-018-0933-7

109. Ye F, Gao G, Zou Y, Zheng S, Zhang L, Ou X, et al. circFBXW7 inhibits malignant progression by splicing miR-197-3p and encoding a 185-aa protein in triple-negative breast cancer. Mol Therapy Nucleic acids. (2019) 18:88–98. doi: 10.1016/j.omtn.2019.07.023

110. Yu J, Xu QG, Wang ZG, Yang Y, Zhang L, Ma JZ, et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. (2018) 68:1214–27. doi: 10.1016/j.jhep.2018.01.012

111. Wei Y, Chen X, Liang C, Ling Y, Yang X, Ye X, et al. A noncoding regulatory RNAs network driven by circ-CYL1 acts specifically in the early stages hepatocellular carcinoma. Hepatology. (2019) 71:130–47. doi: 10.1002/hep.30795

112. Wang H, Chen W, Jin M, Hou L, Chen X, Zhang R, et al. CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by splicing miR-490-3p and regulating PPM1F expression. Mol Cancer. (2018) 17:165. doi: 10.1186/s12943-018-0909-7

113. Chen G, Shi Y, Liu M, Sun J, circHIPK3 regulates cell proliferation and migration by splicing miR-124 and regulating AQP3 expression in hepatocellular carcinoma. Cell Death Dis. (2018) 9:175. doi: 10.1038/s41419-017-0204-3

114. Zhang PF, Wei CY, Huang XY, Peng R, Yang X, Lu JC, et al. Circular RNA circTRIM33-12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression. Mol Cancer. (2019) 18:105. doi: 10.1186/s12943-019-1031-1

115. Zhang L, Zhou Q, Qiu Q, Hou L, Wu M, Li J, et al. CircPLEKH3M3 acts as a tumor suppressor through regulation of the miR-9/BCRA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer. Mol Cancer. (2018) 19:144. doi: 10.1186/s12943-019-1080-5

116. Chen Q, Zhang J, He Y, Wang Y. hsa_circ_0061140 knockdown reverses FOXM1-mediated cell growth and metastasis in ovarian cancer through miR-370 sponge activity. Mol Therapy Nucleic Acids. (2018) 13:55–63. doi: 10.1038/s41388-018-08010

117. Zhang M, Xia B, Xu Y, Zhang Y, Xu J, Lou G. Circular RNA hsa_circ_0051240 promotes cell proliferation, migration and invasion in ovarian cancer through miR-637/KLF4 axis. Artif Cells Nanomedicine Biotechnol. (2019) 47:1224–33. doi: 10.1080/21694012.2019.15

118. Zong ZH, Du YP, Guan X, Chen S, Zhao Y. Circular RNA circWHSC1 promotes ovarian cancer progression by regulating MUC1 and IiTERT through splicing miR-145 and miR-1182. J Exp Clin Cancer Res. (2019) 38:437. doi: 10.1186/s13046-019-1437-z
122. Jin C, Zhao W, Zhang Z, Liu W. Silencing circular RNA circZNF609 restrains growth, migration and invasion by up-regulating microRNA-186-5p in prostate cancer. Artif Cells Nanomed And Biotechnol. (2019) 47:3550–8. doi: 10.1080/21691401.2019.1684281

123. Feng Y, Yang Y, Zhao X, Fan Y, Zhou L, Rong J, et al. Circular RNA circ0005276 promotes the proliferation and migration of prostate cancer cells by interacting with FUS to transcriptionally activate XIAP. Cell Death Dis. (2019) 10:792. doi: 10.1186/s11419-019-2028-9

124. An Y, Cai H, Zhang Y, Liu S, Duan Y, Sun D, et al. circ2MYM2 competed endogenously with miR-335-5p to regulate JMJD2C in pancreatic cancer. Cell Physiol Biochem. (2018) 51:2224–36. doi: 10.1159/000495868

125. Huang WJ, Wang Y, Liu S, Yang J, Guo SX, Wang L, et al. Silencing circular RNA hsa_circ_0009977 suppresses pancreatic ductal adenocarcinoma progression by stimulating miR-874-5p and inhibiting PLK1 expression. Cancer Lett. (2018) 422:70–80. doi: 10.1016/j.canlet.2018.02.014

126. Chen Y, Li Z, Zhang M, Wang B, Ye J, Zhang Y, et al. Circ-Ash2l promotes tumor progression by sponging miR-34a to regulate Notch1 in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. (2019) 38:666. doi: 10.1186/s13046-019-1436-0

127. Wang R, Zhang S, Chen X, Li N, Li J, R. et al. CircNT5E Acts as a sponge of miR-422a to promote glioblastoma tumorigenesis. Mol Oncol. (2017) 11:422–37. doi: 10.1007/82-012-12045

128. Pan B, Qin J, Liu X, He B, Wang X, Pan Y, et al. Identification of circ0005276 as a novel biomarker for colorectal cancer. FEBS Lett. (2018) 592:3069–75. doi: 10.1016/j.febslet.2018.04.035

129. Shao Y, Li J, Lu R, Li T, Yang Y, Xiao B, et al. Global circular RNA expression profile of human gastric cancer and its clinical significance. Cancer Med. (2017) 6:1173–80. doi: 10.1002/cam4.1055

130. Zhu X, Wang X, Wei S, Chen Y, Chen Y, Fan X, et al. hsa_circ_0013958: a novel circular RNA biomarker for hepatocellular carcinoma. World J Gastroenterol. (2017) 23:6360–8. doi: 10.3748/wjg.v23.i4.6330

131. Sun H, Tang W, Rong D, Jin H, Fu K, Zhang W, et al. Hsa_circ_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma. Cancer Biomark. (2018) 21:299–306. doi: 10.3233/CBM-170739

132. Li Z, Liu X, Chen S, Mo X, Li T, Xiao B, et al. Circular RNA circ0009906 affects cell growth and migration in gastric cancer. Br J Cancer. (2017) 116:626–33. doi: 10.1038/bjc.2016.451

133. Zhu X, Wang W, Chen Y, Chen Y, Fan X, et al. hsa_circ_0000356: a circular RNA and potential novel biomarker for lung adenocarcinoma. FEBS J. (2018) 284:2170–82. doi: 10.1111/febs.14132

134. Li J, Wang J, Chen Z, Chen Y, Jin M. Hsa_circ_0079530 promotes cell proliferation and invasion in non-small cell lung cancer. Gene. (2018) 665:1–5. doi: 10.1016/j.gene.2018.04.059

135. Zong L, Sun Q, Zhang H, Chen Z, Deng Y, Li D, et al. Increased expression of circRNA_102231 in lung cancer and its clinical significance. Biomed Pharmacotherapy. (2018) 102:639–44. doi: 10.1016/j.biopha.2018.03.084

136. Li NX, Wang ZJ, Ye CX, Zhao BC, Huang XX, Yang L. Circular RNA circVAPA is up-regulated and exerts oncogenic properties by sponging miR-101 in colorectal cancer. Biomed Pharmacotherapy. (2019) 112:108661. doi: 10.1016/j.biopha.2019.108661

137. Li X, Wang J, Zhang C, Lin C, Zhang J, Zhang W, et al. Circular RNA circITGA7 inhibits colorectal cancer growth and metastasis by modulating the Ras pathway and upregulating transcription of its host gene ITGA7. J Pathol. (2018) 246:166–79. doi: 10.1002/path.5125

138. Yang F, Liu XY, Guo JT, Ge N, Zhu P, Liu X, et al. Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer. World J Gastroenterol. (2017) 23:8345–54. doi: 10.3748/wjg.v23.i47.8345

139. Peng P, Xiao-Long M, Chun-Lin Z. Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Int J Biol Sci. (2018) 14:321–30. doi: 10.7150/ijbs.24360

140. Qu L, Huang Y, Li Z, Dong X, Chen G, Xu H, et al. Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma. Mol Oncol. (2019) 13:414–51. doi: 10.1002/1878-0261.12042

141. He R, Liu P, Xie X, Zhou Y, Liao Q, Liu X, et al. circRNA profiling in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res. (2017) 36:145. doi: 10.1186/s13046-017-0614-1

142. Zhang S, Zeng X, Ding T, Guo L, Li Y, Ou S, et al. Microarray profile of circular RNAs identifies hsa_circ_0014310 as a new circular RNA biomarker in non-small cell lung cancer. Sci Rep. (2018) 8:2878. doi: 10.1038/s41598-018-21300-5

143. Li P, Chen S, Chen H, Mo X, Li T, Shao Y, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta Int J Clin Lab Res. (2015) 444:132–55. doi: 10.1016/j.cca.2015.02.018

144. Xu H, Wang C, Song H, Xu Y, Ji G. RNA-Seq profiling of circular RNAs in human colorectal Cancer liver metastasis and the potential biomarkers. Mol Cancer. (2019) 18,8, doi: 10.1186/s12948-018-0932-8
161. Huang X, Li Z, Zhang Q, Wang W, Li B, Wang L, et al. Circular RNA AKT3 upregulates PI3K/Akt1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. *Mol Cancer.* (2019) 18:71. doi: 10.1186/s12943-019-0969-3

162. Dong W, Dai ZH, Liu FC, Guo XG, Ge CM, Ding J, et al. The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production. *EBioMedicine.* (2019) 45:155–67. doi: 10.1016/j.ebiom.2019.06.030

163. Huang XY, Huang ZL, Xu YH, Zheng Q, Chen Z, Song W, et al. Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-100338/miR-141-3p pathway in hepatitis B-related hepatocellular carcinoma. *Sci Rep.* (2017) 7:5428. doi: 10.1038/s41598-017-05432-8

164. Li S, Gu H, Huang Y, Peng Q, Zhou R, Yi P, et al. Circular RNA 101368/miR-200a axis modulates the migration of hepatocellular carcinoma through HMGB1/RAGE signaling. *Cell Cycle.* (2018) 17:2349–59. doi: 10.1080/15384101.2018.1526599

165. Meng J, Chen S, Han JX, Qian B, Wang XR, Zhong WL, et al. Twist1 regulates vimentin through Cud2 circular RNA to promote EMT in hepatocellular carcinoma. *Cancer Res.* (2018) 78:4150–62. doi: 10.1158/0008-5472.CAN-17-3009

166. Li J, Zhang PY, Li P, Xie JW, Wang JB, Lin JX, et al. Circular RNA hsa_circRNA_002178 silencing retards breast cancer progression via microRNA-328-3p-mediated inhibition of COL1A1. *J Cell Mol Med.* (2020) 24:2189–201. doi: 10.1111/jcmm.14875

167. Yu X, Yao Y, Leng K, Ji D, Qu L, Liu Y, et al. Increased expression of circular RNA circ_0005230 indicates dismal prognosis in breast cancer and regulates cell proliferation and invasion via miR-618/CRX8 signal pathway. *Cell Physiol Biochem.* (2018) 51:1710–22. doi: 10.1159/000495675

168. Li Y, Wan B, Liu L, Zhou L, Zeng Q. Circular RNA circMTO1 suppresses bladder cancer metastasis by sponging miR-221 and inhibiting epithelial-to-mesenchymal transition. *Biochem Biophys Res Commun.* (2019) 508:991–6. doi: 10.1016/j.bbrc.2018.12.046

169. Su H, Tao T, Yang Z, Kang X, Zhang X, Kang D, et al. Circular RNA cTFRC acts as the sponge of MiR-107 to promote bladder carcinoma progression. *Mol Cancer.* (2019) 18:27. doi: 10.1186/s12943-019-0951-0

170. Li J, Li Z, Jiang P, Peng M, Zhang X, Chen K, et al. Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. *J Exp Clin Cancer Res.* (2018) 37:177. doi: 10.1186/s13046-018-0822-3

171. Kun-Peng Z, Chun-Lin Z, Jian-Ping H, Lei Z. A novel circulating hsa_circ_0081001 act as a potential biomarker for diagnosis and prognosis of osteosarcoma. *Int J Biol Sci.* (2018) 14:1513–20. doi: 10.7150/ijbs.27523

172. Yang M, Li G, Fan L, Zhang G, Xu J, Zhang J. Circular RNA circ_0034642 elevates BATF3 expression and promotes cell proliferation and invasion through miR-1205 in glioma. *Biochem Biophys Res Commun.* (2019) 508:980–5. doi: 10.1016/j.bbrc.2018.12.052

173. Jost I, Shalamova LA, Gerresheim GK, Niepmann M, Bindereif A, Rossbach O. Functional sequestration of microRNA-122 from Hepatitis C Virus by circular RNA sponges. *RNA Biol.* (2018) 15:1032–9. doi: 10.1080/15476286.2018.1435248

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Liu, Zhang, Yan and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.